Claims for Patent: 6,071,517

Summary for Patent: 6,071,517

Title:	Bispecific heteroantibodies with dual effector functions
Abstract:	Bispecific molecules which react both with the high-affinity Fc.gamma. receptor of human effector cells and with a target cell surface antigen are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against cells bearing the target antigen. For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fc.gamma. receptor antibody and the binding region derived from an antibody specific for the target antigen. Targeted effector cells can be used to destroy cells bearing the target cell surface antigen by cell-mediated antibody dependent cytolysis and by complement-fixation.
Inventor(s):	Fanger; Michael W. (Lebanon, NH), Guyre; Paul M. (Hanover, NH), Ball; Edward D. (Norwich, VT)
Assignee:	Medarex, Inc. (NJ)
Application Number:	08/359,931
Patent Claims:	1. A heteroantibody comprising a first antibody or fragment thereof which binds to a cell surface antigen and a second antibody or fragment thereof which binds to the high affinity Fc-.gamma. receptor of an effector cell without being blocked by human immunoglobulin G, wherein said heteroantibody is capable of inducing complement mediated and effector-cell-mediated cell lysis. 2. The heteroantibody of claim 1, wherein the first antibody or fragment thereof comprises an IgM molecule. 3. The heteroantibody of claim 1, wherein the first antibody or fragment thereof binds to a CD15 cell surface antigen and the second antibody or fragment thereof binds to the high affinity Fc-.gamma. receptor of an effector cell. 4. The heteroantibody of claim 3, wherein the first antibody or fragment thereof comprises an IgM molecule. 5. The heteroantibody of claim 3, wherein the first antibody or fragment thereof and the second antibody or fragment thereof are linked by a disulfide bridge. 6. The heteroantibody of claim 3, wherein the second antibody or fragment thereof is a monoclonal antibody which is produced by the hybridoma having ATCC accession number HB 9469. 7. The heteroantibody of claim 3, wherein the second antibody fragment is an FAb fragment of the monoclonal antibody produced by the hybridoma having ATCC accession number HB 9469. 8. The heteroantibody of claim 3, wherein the effector cell is a human cell selected from the group consisting of monocytes, macrophages, neutrophils and eosinophils. 9. The heteroantibody of claim 3, wherein the CD15 cell surface antigen is present in a tumor cell which is selected from the group consisting of myeloid leukemia, lung small cell carcinoma, colon carcinoma and breast carcinoma. 10. The heteroantibody of claim 1, wherein the first antibody or fragment thereof comprises mAb PM81 which is produced by the hybridoma having ATCC accession number CRL 10266, and the second antibody or fragment thereof comprises mAb 32.2 which is produced by the hybridoma having ATCC accession number HB 9469. 11. A heteroantibody of claim 1, wherein the cell surface antigen is a breast carcinoma antigen. 12. A target-specific effector cell comprising: a) an effector cell expressing high affinity receptor for the Fc portion of IgG; and b) the heteroantibody of claim 11. 13. A method of tumor therapy comprising, administering to a patient afflicted with a tumor, a therapeutic amount of the target-specific effector cells of claim 12. 14. A heteroantibody of claim 1, wherein the cell surface antigen is an ovarian carcinoma antigen. 15. A target-specific effector cell comprising: a) an effector cell expressing high affinity receptor for the Fc portion of IgG; and b) the heteroantibody of claim 14. 16. A method of tumor therapy comprising, administering to a patient afflicted with a tumor, a therapeutic amount of the target-specific effector cells of claim 15. 17. A target-specific effector cell comprising: a) an effector cell expressing high affinity receptor for the Fc portion of IgG; and b) a heteroantibody which is bound to an epitope of the Fc receptor of the effector cell that is outside of the ligand binding domain of the receptor, and is capable of inducing complement-mediated and effector cell-mediated cell lysis, said heteroantibody comprising: (i) a first antibody or fragment thereof which binds to a CD15 cell surface antigen; and (ii) a second antibody or fragment thereof which binds to an effector cell high affinity Fc.gamma. receptor without being blocked by human immunoglobulin G. 18. A target-specific cell of claim 17, wherein the first antibody or fragment thereof comprises an IgM. 19. A target-specific effector cell of claim 17, wherein the first antibody or fragment thereof and the second antibody or fragment thereof are linked by a disulfide bridge. 20. A target-specific effector cell of claim 17, wherein the second antibody or fragment thereof is produced by the hybridoma having ATCC accession number HB 9469. 21. A target specific effector cell of claim 17, wherein the antibody fragment which binds to the high affinity Fc-.gamma. receptor is an FAb fragment of the monoclonal antibody produced by the hybridoma having ATCC accession number HB 9469. 22. A target-specific effector cell of claim 17, wherein the effector cell is a human cell selected from the group consisting of monocytes, macrophages, neutrophils and eosinophils. 23. A target specific effector cell of claim 17, wherein the tumor cell is selected from the group consisting of myeloid leukemia, lung small cell carcinoma, colon carcinoma and breast carcinoma. 24. A target-specific effector cell comprising: a) an effector cell expressing high affinity Fc-.gamma. receptor; b) a heteroantibody which is bound to an epitope of the Fc receptor of the effector cell that is outside the binding domain of the receptor, and is capable of inducing complement-mediated and effector cell-mediated cell lysis, said heteroantibody comprising: (i) mAb PM81 which is produced by the hybridoma having ATCC accession number CRL 10266; and (ii) mAb 32.2 which is produced by the hybridoma having ATCC accession number HB 9469. 25. A method of tumor therapy, comprising administering to a patient afflicted with a tumor, a therapeutic amount of a targeted effector cell comprising: (i) an antibody or fragment thereof which binds to a CD15 cell surface antigen; and (ii) an antibody or fragment thereof which binds to a high affinity Fc-.gamma. receptor on an effector cell without being blocked by human immunoglobulin G. 26. The method of claim 25, wherein the antibody which binds to CD15 comprises an IgM. 27. The method of claim 25, wherein the antibody or fragment thereof which binds to CD15 and the antibody or fragment thereof which binds to the high affinity Fc-.gamma. receptor are linked by a disulfide bridge. 28. The method of claim 25, wherein the antibody or fragment thereof which binds to the high affinity Fc-.gamma. receptor is produced by the hybridoma having ATCC accession number HB 9469. 29. The method of claim 25, wherein the antibody fragment which binds to the high affinity Fc-.gamma. receptor is an FAb fragment of the IgG molecule produced by the hybridoma having ATCC accession number HB 9469. 30. The method of claim 25, wherein the effector cell is a human cell selected from the group consisting of monocytes, macrophages, neutrophils and eosinophils. 31. The method of claim 25, wherein the tumor cell is selected from the group consisting of myeloid leukemia, lung small cell carcinoma, colon carcinoma and breast carcinoma. 32. A method of tumor therapy comprising, administering to a patient afflicted with a tumor, a therapeutic amount of a target-specific effector cell comprising: a) an effector cell expressing a high affinity Fc-.gamma. receptor; b) a heteroantibody which is bound to an epitope of the Fc receptor of the effector cell that is outside the binding domain of the receptor, and is capable of inducing complement-mediated and effector cell-mediated cell lysis, said heteroantibody comprising: (i) mAb PM81 which is produced by the hybridoma having ATCC accession number CRL 10266; and (ii) mAb 32.2 which is produced by the hybridoma having ATCC accession number HB 9469. 33. A method of inducing cell lysis comprising contacting a target cell with a heteroantibody comprising: a first antigen binding region which binds to an Fc receptor for IgG without being blocked by IgG; and a second antigen binding region which binds to a target epitope. 34. The method of claim 33, wherein the first antigen binding region is derived from a monoclonal antibody produced by the hybridoma cell line having ATCC accession number HB 9469. 35. The method of claim 33, wherein the second antigen binding region binds to a CD15 cell surface antigen. 36. The method of claim 33, wherein the second antigen binding region is derived from a monoclonal antibody produced by the hybridoma cell line having ATCC accession number CRL 10266. 37. The method of claim 33, wherein the target cell is selected from the group consisting of a tumor cell, an auto-antibody producing cell and an IgE-producing cell. 38. The method of claim 33, wherein the target cell is a tumor cell. 39. The method of claim 38, wherein the tumor cell is selected from the group of tumors consisting of myeloid leukemia, lung small cell carcinoma, colon carcinoma and breast carcinoma. 40. The method of claim 33, wherein the Fc receptor is a high affinity Fc.gamma. receptor. 41. A method of directing an effector cell to a target cell, comprising contacting the effector cell with a heteroantibody comprising: an antigen binding region which binds to a high affinity Fc receptor for IgG without being blocked by human IgG; and an antigen binding region which binds to a target cell. 42. The method of claim 41, wherein the target cell is selected from the group consisting of a tumor cell, an auto-antibody producing cell and an IgE-producing cell. 43. The method of claim 41, wherein the target cell is a tumor cell. 44. The method of claim 41, wherein the effector cell is selected from the group consisting of leukocytes, monocytes, neutrophils, natural killer cells and eosinophils.

Details for Patent 6,071,517

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Ag	CARIMUNE, CARIMUNE NF, PANGLOBULIN, SANDOGLOBULIN	immune globulin intravenous (human)	For Injection	102367	07/27/2000		2017-06-06
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	07/26/2007		2017-06-06
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	10/02/2009		2017-06-06
Csl Behring Ag	PRIVIGEN	immune globulin intravenous (human), 10% liquid	Injection	125201	02/07/2013		2017-06-06
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	09/17/2009		2017-06-06
Bio Products Laboratory	GAMMAPLEX	immune globulin intravenous (human)	Injection	125329	02/06/2017		2017-06-06